DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements about the company's growth potential and operational capabilities [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Iovance to contact them to discuss their legal options, particularly in light of a federal securities class action with a deadline of July 14, 2025, for seeking the role of lead plaintiff [1][2]. - The complaint against Iovance alleges that the company and its executives made false or misleading statements and failed to disclose the true state of the company's growth potential [4]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full year, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [5]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [5].